vs

Side-by-side financial comparison of Mind Medicine (MindMed) Inc. (DFTX) and Tron Inc. (TRON). Click either name above to swap in a different company.

Tron Inc. is the larger business by last-quarter revenue ($1.2M vs $906.0K, roughly 1.3× Mind Medicine (MindMed) Inc.). Tron Inc. runs the higher net margin — -2476.3% vs -2634.0%, a 157.7% gap on every dollar of revenue. On growth, Tron Inc. posted the faster year-over-year revenue change (30.7% vs -16.1%).

Definium Therapeutics, Inc., formerly known as MindMed, is a New York-based biotechnology company that is currently developing clinical and therapeutic applications for psychedelic and, more broadly, psychoplastogenic drugs.

Tron is a decentralized, proof-of-stake blockchain with smart contract functionality. The cryptocurrency native to the blockchain is known as Tronix (TRX). It was founded in March 2014 by Justin Sun and, since 2017, has been overseen and supervised by the TRON Foundation, a non-profit organization in Singapore, established in the same year. It is open-source software.

DFTX vs TRON — Head-to-Head

Bigger by revenue
TRON
TRON
1.3× larger
TRON
$1.2M
$906.0K
DFTX
Growing faster (revenue YoY)
TRON
TRON
+46.8% gap
TRON
30.7%
-16.1%
DFTX
Higher net margin
TRON
TRON
157.7% more per $
TRON
-2476.3%
-2634.0%
DFTX

Income Statement — Q4 FY2023 vs Q4 FY2025

Metric
DFTX
DFTX
TRON
TRON
Revenue
$906.0K
$1.2M
Net Profit
$-23.9M
$-29.8M
Gross Margin
28.3%
Operating Margin
-2450.8%
Net Margin
-2634.0%
-2476.3%
Revenue YoY
-16.1%
30.7%
Net Profit YoY
-386.7%
-2943.1%
EPS (diluted)
$-0.58
$-0.17

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
DFTX
DFTX
TRON
TRON
Q4 25
$1.2M
Q3 25
$1.1M
Q2 25
$1.3M
Q1 25
$1.1M
Q4 24
$920.7K
Q3 24
$876.4K
Q2 24
$1.5M
Q1 24
$1.0M
Net Profit
DFTX
DFTX
TRON
TRON
Q4 25
$-29.8M
Q3 25
$12.2M
Q2 25
$1.5M
Q1 25
$-646.6K
Q4 24
$-979.5K
Q3 24
$-1.1M
Q2 24
$-521.0K
Q1 24
$-1.7M
Gross Margin
DFTX
DFTX
TRON
TRON
Q4 25
28.3%
Q3 25
27.0%
Q2 25
21.8%
Q1 25
24.5%
Q4 24
18.5%
Q3 24
22.4%
Q2 24
21.5%
Q1 24
16.3%
Operating Margin
DFTX
DFTX
TRON
TRON
Q4 25
Q3 25
-59.5%
Q2 25
-55.4%
Q1 25
Q4 24
Q3 24
-129.2%
Q2 24
-34.9%
Q1 24
Net Margin
DFTX
DFTX
TRON
TRON
Q4 25
-2476.3%
Q3 25
1102.4%
Q2 25
109.3%
Q1 25
-59.3%
Q4 24
-106.4%
Q3 24
-128.8%
Q2 24
-34.5%
Q1 24
-169.9%
EPS (diluted)
DFTX
DFTX
TRON
TRON
Q4 25
$-0.17
Q3 25
$0.04
Q2 25
$0.01
Q1 25
$-0.04
Q4 24
$-0.04
Q3 24
$-0.11
Q2 24
$-0.05
Q1 24
$-0.17

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
DFTX
DFTX
TRON
TRON
Cash + ST InvestmentsLiquidity on hand
$99.7M
Total DebtLower is stronger
Stockholders' EquityBook value
$78.1M
$210.3M
Total Assets
$124.5M
$211.4M
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Stockholders' Equity
DFTX
DFTX
TRON
TRON
Q4 25
$210.3M
Q3 25
$239.8M
Q2 25
$111.4M
Q1 25
$5.0M
Q4 24
$5.3M
Q3 24
$3.3M
Q2 24
$3.1M
Q1 24
$3.3M
Total Assets
DFTX
DFTX
TRON
TRON
Q4 25
$211.4M
Q3 25
$244.6M
Q2 25
$112.2M
Q1 25
$5.8M
Q4 24
$6.3M
Q3 24
$5.7M
Q2 24
$3.4M
Q1 24
$3.8M

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
DFTX
DFTX
TRON
TRON
Operating Cash FlowLast quarter
$-20.6M
$-1.4M
Free Cash FlowOCF − Capex
FCF MarginFCF / Revenue
Capex IntensityCapex / Revenue
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
DFTX
DFTX
TRON
TRON
Q4 25
$-1.4M
Q3 25
$-850.0K
Q2 25
$40.9K
Q1 25
$-206.5K
Q4 24
$-2.9M
Q3 24
$-176.4K
Q2 24
$-334.3K
Q1 24
$-1.2M
Cash Conversion
DFTX
DFTX
TRON
TRON
Q4 25
Q3 25
-0.07×
Q2 25
0.03×
Q1 25
Q4 24
Q3 24
Q2 24
Q1 24

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons